Skip to main content
. 2018 Mar 15;40(3):213–218. doi: 10.1016/j.htct.2018.01.002

Figure 1.

Figure 1

Gates strategy used according to recommendations of the International Society of Hemotherapy and Graft Engineering (ISHAGE). (A) Region positive for CD45 cells representing all leucocytes (R1 gate). (B) Positive for CD34 from immature cells (R2 gate). (C) Combined events of R1 and R2 with Gate R3 selecting CD45+ low complexity cells. (D) Cells selected by FSC/SSC and the percentage of CD34+ cells was determined (R4 gate).